NICE backpedals on decision to limit access to Roche's Tarceva | PharmaBoardroom
written on 04.04.2014
Tags:
,

NICE backpedals on decision to limit access to Roche's Tarceva

TAGS: ,

NICE has made a U-turn on its decision to restrict the use of Roche's Tarceva (erlotinib) in second-line non-small cell lung cancer (NSCLC).

Latest Report